United States - English - NLM (National Library of Medicine)

eugia us llc - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - initial treatment of advanced ovarian carcinoma carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. secondary treatment of advanced ovarian carcinoma carboplatin injection is indicated for the palliative trea

United States - English - NLM (National Library of Medicine)

bpi labs llc - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - initial treatment of advanced ovarian carcinoma carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. secondary treatment of advanced ovarian carcinoma carboplatin injection is indicated for the palliative treatm

Australia - English - Department of Health (Therapeutic Goods Administration)

novotech australia pty ltd - carboplatin -

Australia - English - Department of Health (Therapeutic Goods Administration)

novotech australia pty ltd - carboplatin -

Australia - English - Department of Health (Therapeutic Goods Administration)

novotech australia pty ltd - carboplatin -

Malta - English - Medicines Authority

fresenius kabi oncology plc - carboplatin - concentrate for solution for infusion - carboplatin 10 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

fresenius kabi oncology plc - carboplatin - concentrate for solution for infusion - carboplatin 10 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

fresenius kabi oncology plc - carboplatin - concentrate for solution for infusion - carboplatin 10 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

fresenius kabi oncology plc - carboplatin - concentrate for solution for infusion - carboplatin 10 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

fresenius kabi italia s.r.l via camagre 41, 37063 isola della scala (vr) , italy - carboplatin - concentrate for solution for infusion - carboplatin 10 mg/ml - antineoplastic agents